Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation.
Atrial fibrosis has been strongly associated with the presence of heart diseases/arrhythmias, including congestive heart failure (CHF) and atrial fibrillation (AF). Inducibility of AF as a result of atrial fibrosis has been the subject of intense recent investigation since it is the most commonly encountered arrhythmia in adults and can substantially increase the risk of premature death. Rhythm and rate control drugs as well as surgical interventions are used as therapies for AF; however, increased attention has been diverted to mineralocorticoid receptor (MR) antagonists including spironolactone as potential therapies for human AF because of their positive effects on reducing atrial fibrosis and associated AF in animal models. Spironolactone has been shown to exert positive effects in human patients with heart failure; however, the mechanisms and effects in human atrial fibrosis and AF remain undetermined. This review will discuss and highlight developments on (i) the relationship between atrial fibrosis and AF, (ii) spironolactone, as a drug targeted to atrial fibrosis and AF, as well as (iii) the distinct and common mechanisms important for regulating atrial and ventricular fibrosis, inclusive of the key extracellular matrix regulatory proteins involved.
Pellman
Jason
J
Department of Medicine, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0613, USA.
Lyon
Robert C
RC
Sheikh
Farah
F
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D005109:Extracellular Matrix / Q000378:metabolism*; D005355:Fibrosis / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D006325:Heart Atria / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D015398:Signal Transduction / Q000187:drug effects; D013148:Spironolactone / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D013148:Spironolactone